Otsuka Pharmaceutical Company, Limited

Educational Foundation Jichi Medical University

Shigeto Yoshida

Makoto Matsumoto

Norimitsu Hariguchi

Yoshihiro Goto

Masanori Kawasaki

Yoshio Ohba

Masami Mizukoshi

Masahiro Saito

Katsuya Inagaki

Kuniko Hirota

Toshiki Sudo

The present invention provides a novel transfer vector and a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient, which are useful as preventive or therapeutic drugs for infectious diseases such as malaria and influenza; and methods for preventing and treating infectious diseases such as malaria and influenza. More specifically, the invention provides a recombinant transfer vector capable of expressing a foreign gene fused to a virus gene under the control of a dual promoter; a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient; and methods for preventing and treating infectious diseases such as malaria and influenza comprising administrating the recombinant baculovirus to patients.

Recombinant baculovirus vaccine

A recombinant transfer vector capable of expressing a foreign gene fused to a viral gene under the control of dual promoters and a recombinant baculovirus, and methods for production thereof, as well as pharmaceuticals comprising the recombinant baculovirus as an active ingredient.

The invention provides a pharmaceutical composition comprising at least one polypeptide of the following (a) to (d): (a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1; (b) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (a) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity;(c) a polypeptide comprising the amino acid sequence of SEQ ID NO:3; and(d) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (c) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity,as an active component.

Platelet aggregation inhibitor composition

The invention provides a pharmaceutical composition comprising at least one polypeptide of the following (a) to (d):

Growing community of inventors

Shimotsuke, Japan

Shigeto Yoshida